ClinicalTrials.gg
DrugBiological

Ifinatamab deruxtecan clinical trials

Also written DS-7300a and MK-2400.

studies test it
17
open now
14
in phase 3
3
first study started
2019

How each study uses ifinatamab deruxtecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ifinatamab deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ifinatamab deruxtecan
12
I-DXd
11
Ifinatamab Deruxtecan (I-DXd)
4

Development codes

DS-7300a
10
MK-2400
9

Studies by the year they started

17 studies that test it; most in 2025 (7)

Studies that test ifinatamab deruxtecan, by start year
YearStudies
20192
20221
20243
20257
20264

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
14
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 1

Merck Sharp & Dohme LLC (10) · Daiichi Sankyo (6) · Rahul Aggarwal (1)

Often tested with

Tested in the same studies.

Raludotatug deruxtecan (2) · Gocatamig (2) · 5-HT3 antagonists (1) · NK1 receptor antagonists (1) · Sacituzumab tirumotecan (1) · Vibostolimab (1) · Boserolimab (1) · Anti-ILT4 Monoclonal Antibody MK-4830 (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test ifinatamab deruxtecan.

Studies

Open first, then newest update. How each study uses ifinatamab deruxtecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 1 — ifinatamab deruxtecan is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call ifinatamab deruxtecan · ClinicalTrials.gg INT016190

  • UNII (FDA) C6I0GC0GX5IFINATAMAB DERUXTECANOne source FDA
  • NCI Thesaurus C171577Ifinatamab DeruxtecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.